These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 37919190

  • 1. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    de Vos II, Remmers S, Hogenhout R, Roobol MJ, ERSPC Rotterdam Study GroupErasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands..
    Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
    [Abstract] [Full Text] [Related]

  • 2. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
    Remmers S, Bangma CH, Godtman RA, Carlsson SV, Auvinen A, Tammela TLJ, Denis LJ, Nelen V, Villers A, Rebillard X, Kwiatkowski M, Recker F, Wyler S, Zappa M, Puliti D, Gorini G, Paez A, Lujan M, Nieboer D, Schröder FH, Roobol MJ.
    Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
    [Abstract] [Full Text] [Related]

  • 3. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, ERSPC Rotterdam Study GroupErasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands..
    Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
    [Abstract] [Full Text] [Related]

  • 4. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
    Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH, ERSPC Rotterdam Study Group.
    Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
    [Abstract] [Full Text] [Related]

  • 5. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [Abstract] [Full Text] [Related]

  • 6. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ.
    Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
    [Abstract] [Full Text] [Related]

  • 8. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV, Qiao EM, Kotha NV, Qian AS, Rose BS.
    JAMA Oncol; 2022 Oct 01; 8(10):1471-1476. PubMed ID: 35925581
    [Abstract] [Full Text] [Related]

  • 9. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.
    Eur Urol; 2013 Apr 01; 63(4):627-33. PubMed ID: 22841675
    [Abstract] [Full Text] [Related]

  • 10. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.
    Eur Urol; 2012 Jan 01; 61(1):171-6. PubMed ID: 21840117
    [Abstract] [Full Text] [Related]

  • 11. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug 01; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 12. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec 01; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 13. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
    Hogenhout R, Remmers S, van Slooten-Midderigh ME, de Vos II, Roobol MJ, ERSPC Rotterdam Study GroupDepartment of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands..
    Eur Urol Oncol; 2024 Aug 01; 7(4):713-720. PubMed ID: 37690917
    [Abstract] [Full Text] [Related]

  • 14. Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    Cirulli GO, Davis M, Stephens A, Chiarelli G, Finati M, Corsi N, Williams E, Affas R, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F.
    J Urol; 2024 Oct 01; 212(4):560-570. PubMed ID: 39079152
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE.
    Eur Urol; 2012 May 01; 61(5):865-74. PubMed ID: 22104593
    [Abstract] [Full Text] [Related]

  • 16. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.
    Eur Urol; 2015 Sep 01; 68(3):354-60. PubMed ID: 25556937
    [Abstract] [Full Text] [Related]

  • 17. The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam.
    Remmers S, Nieboer D, Roobol MJ, ERSPC Rotterdam Study Group.
    Eur Urol Open Sci; 2023 May 01; 51():1-6. PubMed ID: 37187725
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.